Aerovate Therapeutics, Inc. Liabilities, Current in USD from Q4 2020 to Q3 2025

Taxonomy & unit: us-gaap: USD
Description: Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Summary: Aerovate Therapeutics, Inc. quarterly Liabilities, Current history and growth rate from Q4 2020 to Q3 2025.
Aerovate Therapeutics, Inc. Liabilities, Current for the quarter ending September 30, 2025 was $22.4M, a 117% increase year-over-year.

Liabilities, Current, Quarterly (USD)

Liabilities, Current, YoY Quarterly Growth (%)

Aerovate Therapeutics, Inc. Quarterly Liabilities, Current (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed
Q3 2025	$22.4M	+$12M	+117%	Sep 30, 2025	10-Q	2025-11-14
Q2 2025	$21.6M	+$4.6M	+27%	Jun 30, 2025	10-Q	2025-08-13
Q1 2025	$2.42M	-$13.1M	-84.4%	Mar 31, 2025	10-Q	2025-04-25
Q4 2024	$12M	-$5.64M	-32%	Dec 31, 2024	10-Q	2025-11-14
Q3 2024	$10.3M	-$4.41M	-29.9%	Sep 30, 2024	10-Q	2024-11-12
Q2 2024	$17M	+$3.74M	+28.1%	Jun 30, 2024	10-Q	2024-08-12
Q1 2024	$15.5M	+$4.88M	+45.9%	Mar 31, 2024	10-Q	2024-05-13
Q4 2023	$17.6M	+$9.86M	+127%	Dec 31, 2023	10-K	2025-03-27
Q3 2023	$14.7M	+$7.02M	+91.1%	Sep 30, 2023	10-Q	2023-11-13
Q2 2023	$13.3M	+$9.53M	+254%	Jun 30, 2023	10-Q	2023-08-14
Q1 2023	$10.6M	+$5.93M	+126%	Mar 31, 2023	10-Q	2023-05-15
Q4 2022	$7.78M	+$5.23M	+205%	Dec 31, 2022	10-K	2024-03-25
Q3 2022	$7.71M	+$3.88M	+101%	Sep 30, 2022	10-Q	2022-11-14
Q2 2022	$3.76M	-$437K	-10.4%	Jun 30, 2022	10-Q	2022-08-15
Q1 2022	$4.7M			Mar 31, 2022	10-Q	2022-05-16
Q4 2021	$2.55M	+$776K	+43.7%	Dec 31, 2021	10-K	2023-03-29
Q3 2021	$3.83M			Sep 30, 2021	10-Q	2021-11-15
Q2 2021	$4.19M			Jun 30, 2021	10-Q	2021-08-16
Q4 2020	$1.77M			Dec 31, 2020	10-K	2022-03-30

* An asterisk sign (*) next to the value indicates that the value is likely invalid.